美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Gilteritinib Fumarate	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 15, 20, 30 and 45	2020/08/27
Glimepiride	Tablet	II (Paddle)	75	Phosphate Buffer, pH 7.8	900	5, 10, 15 and 30	2004/07/23
Glimepiride/Pioglitazone HCl	Tablet	II (Paddle)	75	For Pioglitazone: pH 2.0, HCl Buffer. For Glimepiride: pH 6.8, Sodium Phosphate Buffer with 0.2% sodium dodecyl sulfate	900	For Pioglitazone: 10, 15, 20, 30 and 45; For Glimepiride: 10, 15, 20 and 30	2009/04/02
Glimepiride/Rosiglitazone Maleate	Tablet	II (Paddle)	75	0.01 M HCl with 0.5% Sodium Dodecyl Sulfate	900	5, 10, 15, 30, 45 and 60	2007/01/03
Glipizide	Tablet (Extended Release)	II (Paddle)	50	Simulated Intestinal Fluid without pancreatin, pH 7.5	900	1, 2, 4, 8, 16 hours and until at least 80% dissolved	2008/04/10
Glipizide	Tablet			Refer to USP			2010/08/05
Glipizide/Metformin HCL	Tablet			Refer to USP			2008/12/18
Glyburide (Micronized)	Tablet	II (Paddle)	50	0.05 M Phosphate Buffer, pH 7.5	900	10, 20, 30, 45 and 60	2004/02/02
Glyburide (Non-micronized)	Tablet	II (Paddle)	75	0.05 M Borate Buffer, pH 9.5	500	10, 20, 30, 45 and 60	2004/02/02
Glyburide/Metformin HCl	Tablet			Refer to USP			2008/01/14
Glycopyrrolate	Tablet, Oral Disintegrating			Refer to FDA's Dissolution Guidance, 2018			2025/09/08
Glycopyrrolate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Goserelin Acetate	Implant	Prior to sampling, the jar is removed from incubation and mechanically swirled with digital orbital shaker	Swirl orbit of 50 mm at 205 rpm for 6 seconds	Each implant should be incubated in 50 mL of phosphate buffered saline, pH 7.4, at 39°C (warmed overnight before the implants are added), in a 120-mL Wheaton jar.	50	3, 14, 35, 56 and 84 days (10.8 mg strength); 7, 14, 17, 21 and 28 days (3.6 mg strength)	2008/11/04
Granisetron	Injectable (Extended Release)			Develop a method to characterize in vitro release			2016/12/22
Granisetron	Film, Transdermal (Extended Release)	VI (Cylinder)	50	80 microL /L phosphoric acid (85%) at 32 ± 0.5°C	1000	2, 6, 12, 24, 36, 48, 60, 72 and 96 hours	2011/03/03
Granisetron HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Griseofulvin	Oral Suspension			Develop a dissolution method			2023/09/15
Griseofulvin (Microcrystalline)	Oral Suspension			Develop a dissolution method			2023/09/15
Griseofulvin (Microcrystalline)	Tablet			Develop a dissolution method			2024/01/03
Griseofulvin (Ultramicrocrystalline)	Tablet			Develop a dissolution method			2024/01/03